S&P 500   3,798.32 (+0.19%)
DOW   30,397.39 (+0.27%)
QQQ   282.70 (+0.20%)
AAPL   146.72 (+0.42%)
MSFT   249.67 (+0.32%)
META   139.47 (-0.58%)
GOOGL   101.51 (-0.13%)
AMZN   121.25 (+0.13%)
TSLA   240.42 (-3.62%)
NVDA   132.55 (+0.67%)
NIO   16.07 (-3.95%)
BABA   84.70 (+0.70%)
AMD   68.33 (+0.63%)
T   15.97 (-0.75%)
MU   54.92 (+1.78%)
CGC   3.04 (-3.18%)
F   12.50 (+1.13%)
GE   67.97 (+0.64%)
DIS   100.68 (-0.75%)
AMC   7.40 (-5.49%)
PYPL   94.13 (+1.44%)
PFE   44.24 (-0.49%)
NFLX   237.80 (-1.22%)
S&P 500   3,798.32 (+0.19%)
DOW   30,397.39 (+0.27%)
QQQ   282.70 (+0.20%)
AAPL   146.72 (+0.42%)
MSFT   249.67 (+0.32%)
META   139.47 (-0.58%)
GOOGL   101.51 (-0.13%)
AMZN   121.25 (+0.13%)
TSLA   240.42 (-3.62%)
NVDA   132.55 (+0.67%)
NIO   16.07 (-3.95%)
BABA   84.70 (+0.70%)
AMD   68.33 (+0.63%)
T   15.97 (-0.75%)
MU   54.92 (+1.78%)
CGC   3.04 (-3.18%)
F   12.50 (+1.13%)
GE   67.97 (+0.64%)
DIS   100.68 (-0.75%)
AMC   7.40 (-5.49%)
PYPL   94.13 (+1.44%)
PFE   44.24 (-0.49%)
NFLX   237.80 (-1.22%)
S&P 500   3,798.32 (+0.19%)
DOW   30,397.39 (+0.27%)
QQQ   282.70 (+0.20%)
AAPL   146.72 (+0.42%)
MSFT   249.67 (+0.32%)
META   139.47 (-0.58%)
GOOGL   101.51 (-0.13%)
AMZN   121.25 (+0.13%)
TSLA   240.42 (-3.62%)
NVDA   132.55 (+0.67%)
NIO   16.07 (-3.95%)
BABA   84.70 (+0.70%)
AMD   68.33 (+0.63%)
T   15.97 (-0.75%)
MU   54.92 (+1.78%)
CGC   3.04 (-3.18%)
F   12.50 (+1.13%)
GE   67.97 (+0.64%)
DIS   100.68 (-0.75%)
AMC   7.40 (-5.49%)
PYPL   94.13 (+1.44%)
PFE   44.24 (-0.49%)
NFLX   237.80 (-1.22%)
S&P 500   3,798.32 (+0.19%)
DOW   30,397.39 (+0.27%)
QQQ   282.70 (+0.20%)
AAPL   146.72 (+0.42%)
MSFT   249.67 (+0.32%)
META   139.47 (-0.58%)
GOOGL   101.51 (-0.13%)
AMZN   121.25 (+0.13%)
TSLA   240.42 (-3.62%)
NVDA   132.55 (+0.67%)
NIO   16.07 (-3.95%)
BABA   84.70 (+0.70%)
AMD   68.33 (+0.63%)
T   15.97 (-0.75%)
MU   54.92 (+1.78%)
CGC   3.04 (-3.18%)
F   12.50 (+1.13%)
GE   67.97 (+0.64%)
DIS   100.68 (-0.75%)
AMC   7.40 (-5.49%)
PYPL   94.13 (+1.44%)
PFE   44.24 (-0.49%)
NFLX   237.80 (-1.22%)

Arrowhead Pharmaceuticals - ARWR SEC Filings & 10K Form

$34.27
-0.64 (-1.83%)
(As of 10/5/2022 03:10 PM ET)
Add
Compare
Today's Range
$33.66
$35.00
50-Day Range
$29.63
$48.31
52-Week Range
$26.81
$84.83
Volume
13,507 shs
Average Volume
881,692 shs
Market Capitalization
$3.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.57

Recent Arrowhead Pharmaceuticals SEC Filings

DateFilerForm TypeView
09/30/2022
4:32 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
09/29/2022
4:15 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/12/2022
6:39 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/11/2022
7:08 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/29/2022
6:11 PM
Arrowhead Pharmaceuticals (Issuer)
Oliver Tracie (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/06/2022
4:27 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/10/2022
3:11 PM
Arrowhead Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2022
5:15 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/05/2022
1:26 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2022
6:31 AM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/14/2021
4:25 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2021
3:10 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2021
5:59 PM
Arrowhead Pharmaceuticals (Issuer)
De Backer Marianne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2021
5:44 PM
Arrowhead Pharmaceuticals (Issuer)
Hassard James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2021
3:47 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2021
3:05 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2021
4:15 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2021
5:51 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2021
4:56 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2021
9:30 AM
Arrowhead Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
02/04/2021
3:10 PM
Arrowhead Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
02/04/2021
3:05 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2021
8:54 PM
Arrowhead Pharmaceuticals (Filer)
Form DEF 14A
01/19/2021
4:58 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2021
4:49 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2021
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2021
5:05 PM
Arrowhead Pharmaceuticals (Issuer)
Hassard James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2021
5:11 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2021
5:08 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2021
5:02 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:27 PM
Arrowhead Pharmaceuticals (Issuer)
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:24 PM
Arrowhead Pharmaceuticals (Issuer)
Ferrari Mauro (Reporting)
Ferrari Mauro (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:22 PM
Arrowhead Pharmaceuticals (Issuer)
Arrowhead Pharmaceuticals (Issuer)
De Backer Marianne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:20 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:16 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:14 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:11 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:07 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2021
5:01 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2021
5:02 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2020
4:52 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2020
4:55 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2020
4:55 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2020
5:26 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2020
5:16 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2020
6:07 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
4:58 PM
Arrowhead Pharmaceuticals (Issuer)
Bradshaw Curt (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/23/2020
3:34 PM
Arrowhead Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
11/20/2020
5:03 PM
Arrowhead Pharmaceuticals (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2020
4:49 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2020
5:11 PM
Arrowhead Pharmaceuticals (Issuer)
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/26/2020
5:02 PM
Arrowhead Pharmaceuticals (Issuer)
De Backer Marianne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2020
6:35 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2020
5:02 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/13/2020
5:01 PM
Arrowhead Pharmaceuticals (Issuer)
Ferrari Mauro (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2020
4:00 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/08/2020
5:31 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/08/2020
6:35 AM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2020
5:08 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2020
4:14 PM
Arrowhead Pharmaceuticals (Filer)
Form 424B5
06/26/2020
5:02 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2020
5:10 PM
Arrowhead Pharmaceuticals (Issuer)
De Backer Marianne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2020
5:27 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2020
5:48 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2020
5:45 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2020
6:19 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN BRUCE D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2020
6:00 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN BRUCE D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2020
6:47 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2020
4:18 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/04/2020
1:47 PM
Arrowhead Pharmaceuticals (Subject)
FIRST MANHATTAN CO (Filed by)
Form SC 13G/A
01/28/2020
3:31 PM
Arrowhead Pharmaceuticals (Filer)
Form DEF 14A
01/23/2020
5:15 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2020
4:00 PM
Arrowhead Pharmaceuticals (Filer)
Form PRE 14A
01/13/2020
4:13 PM
Arrowhead Pharmaceuticals (Issuer)
Hassard James (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/08/2020
5:35 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN BRUCE D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2020
5:33 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2020
5:31 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2020
5:10 PM
Arrowhead Pharmaceuticals (Issuer)
De Backer Marianne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2020
5:08 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2020
5:06 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2020
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN BRUCE D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2020
5:02 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2019
3:54 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2019
3:51 PM
Arrowhead Pharmaceuticals (Issuer)
De Backer Marianne (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
12/13/2019
5:35 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2019
8:55 PM
Arrowhead Pharmaceuticals (Filer)
Form 424B5
12/04/2019
5:48 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2019
3:48 PM
Arrowhead Pharmaceuticals (Filer)
Form 424B5
12/02/2019
3:02 PM
Arrowhead Pharmaceuticals (Filer)
Form S-3ASR
11/25/2019
3:11 PM
Arrowhead Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
11/25/2019
3:05 PM
Arrowhead Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2019
5:48 PM
Arrowhead Pharmaceuticals (Issuer)
Bradshaw Curt (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/20/2019
5:44 PM
Arrowhead Pharmaceuticals (Issuer)
San Martin Javier (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/07/2019
5:45 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/01/2019
6:32 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/11/2019
6:31 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2019
9:56 AM
Arrowhead Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G
09/27/2019
8:16 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2019
8:12 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2019
7:09 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
This page (NASDAQ:ARWR) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.